Skip to main content
SpringerLink
Log in

Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of Enfuvirtide

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Enfuvirtide, the first fusion inhibitor approved for the treatment of HIV-1 infection, is a synthetic peptide that binds to HIV-1 glycoprotein 41, blocking the fusion of viral and cellular membranes. When administered subcutaneously at the recommended dose of 90mg twice daily with optimised background antiretroviral therapy, enfuvirtide significantly reduces plasma HIV-1 RNA levels up to 48 weeks compared with optimised background therapy alone.

Enfuvirtide exhibits a small volume of distribution (5.48L), low systemic clearance (1.4 L/h) and high plasma protein binding (92%). Less than 17% of enfuvirtide is converted to a minimally active deaminated form of the parent drug. Both enfuvirtide and its metabolite are primarily eliminated via catabolism to amino acid residues. Following subcutaneous administration, enfuvirtide is almost completely absorbed, and exposure increases almost linearly with dose over the range 45–180mg.

When administered at the recommended dose in adults, subcutaneous absorption is slow and protracted, resulting in relatively flat steady-state plasma concentration-time profiles. Bioavailability is high (84.3%) and the elimination half-life (3.8 hours) supports twice-daily administration. Comparable absorption was observed from three different anatomical injection sites. The pharmacokinetic-pharmacodynamic relationship indicates that the recommended dose, in combination with other active antiretrovirals, is optimal. Enfuvirtide clearance is influenced to a small extent by sex and bodyweight but this does not necessitate dosage adjustment.

In vitro and in vivo studies indicate that enfuvirtide has a low potential to interact with concomitantly administered drugs. Enfuvirtide did not influence concentrations of drugs metabolised by cytochrome P450 (CYP) 3A4, CYP2D6 or N-acetyltransferase, and had only minimal effects on those metabolised by CYP1A2, CYP2E1 or CYP2C19. Coadministration of ritonavir, ritonavir-boosted saquinavir or rifampicin (rifampin) did not result in clinically significant changes in enfuvirtide pharmacokinetics.

In HIV-1-infected paediatric patients, subcutaneous dosages based on bodyweight (2 mg/kg twice daily) produce pharmacokinetics broadly similar to those observed in adults administered 90mg twice daily.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Derdyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency viras type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gpl20 interactions with the coreceptor. J Clin Virol 2001; 75: 8605–14

    Google Scholar 

  2. Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert Opin Invest Drugs 2002; 11: 1837–43

    Article  CAS  Google Scholar 

  3. Fuzeon™ prescribing information. Nutley (NJ): Roche Laboratories, Inc., and Durham (NC): Trimeris, Inc., 2003 Mar

  4. Lalezari J, Henry K, O’Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drag-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175–85

    Article  PubMed  CAS  Google Scholar 

  5. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drag-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186–95

    Article  PubMed  CAS  Google Scholar 

  6. Trottier B, Arastéh K, Henry K, et al. Durability of response of enfuvirtide through 48 weeks in the TORO trials. 43rd Inter-science Conference on Antimicrobial Agents and Chemotherapy; 2004 Sep 14-17; Chicago

    Google Scholar 

  7. Arasteh K, Lazzarin A, Clotet B, et al. Enfuvirtide TORO studies: 96-week efficacy, durability and safety. XV International AIDS Conference; 2004 Jul 11–16; Bangkok

    Google Scholar 

  8. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated viras entry. Nat Med 1998; 4: 1302–7

    Article  PubMed  CAS  Google Scholar 

  9. Schooley RT, Clumeck N, Haubrich R, et al. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. Antivir Ther 2001; 6: 89–96

    PubMed  CAS  Google Scholar 

  10. Mittler J, Essunger P, Yuen GJ, et al. Short-term measures of relative efficacy predict longer-term reduction in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001; 45: 1438–43

    Article  PubMed  CAS  Google Scholar 

  11. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 2003; 34 Suppl. 1: S91–4

    Article  PubMed  CAS  Google Scholar 

  12. Mitsuyasu RT, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. AIDS 1998 Jul; 12: F103–9

    Article  PubMed  CAS  Google Scholar 

  13. Para MF, Meehan P, Holden-Wiltse J, et al. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrob Agents Chemother 1999; 43: 1373–8

    PubMed  CAS  Google Scholar 

  14. Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003; 188: 1652–8

    Article  PubMed  CAS  Google Scholar 

  15. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-infected subjects. AIDS 2003; 17: 2487–94

    Article  PubMed  CAS  Google Scholar 

  16. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18: 685–93

    Article  PubMed  CAS  Google Scholar 

  17. Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003; 8: 279–87

    PubMed  CAS  Google Scholar 

  18. Wheeler DA, Lalezari JP, Kilby JM, et al. Safety, tolerability and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. J Clin Virol 2004; 30(2): 183–90

    Article  PubMed  CAS  Google Scholar 

  19. Zhang X, Nieforth K, Lang J-M, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002; 72: 10–9

    Article  PubMed  CAS  Google Scholar 

  20. Data on file, Roche Pharmaceuticals, 2002 Jul 31

  21. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 2003; 28: 217–22

    Article  PubMed  CAS  Google Scholar 

  22. Fuzeon®: summary of product characteristics. Welwyn Garden City, Hertfordshire: Roche Registration Limited, 2003 May 27

  23. Zhang X, Buss N, Salgo M, et al. Enfuvirtide pharmacokinetic-pharmacodynamic relationship [poster no. 4.1/4]. 9th European AIDS Conference; 2003 Oct 25–29; Warsaw

    Google Scholar 

  24. Boyd MA, Zhang X, Door A, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003; 43: 1382–91

    Article  PubMed  CAS  Google Scholar 

  25. Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004 Jul; 44: 793–803

    Article  PubMed  CAS  Google Scholar 

  26. Zhang X, Lalezari J, Badley A, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004; 75: 558–68

    Article  PubMed  CAS  Google Scholar 

  27. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus-1-infected children. Pediatr Infect Dis J 2002; 21: 653–9

    Article  PubMed  Google Scholar 

  28. Church JA, Hughes M, Chen J, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004 Aug; 23: 713–8

    Article  PubMed  Google Scholar 

  29. Bellibas S, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus-1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004; 23(12): 1137–41

    PubMed  Google Scholar 

  30. Zhang X, Dorr A, Siddique Z, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of enfuvirtide in HIV-1 infected adolescents over 24 weeks of treatment. 105th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2004 Mar 24-27; Miami Beach

    Google Scholar 

Download references

Acknowledgements

Indravadan H. Patel, Xiaoping Zhang, Keith Nieforth and Miklos Salgo are full-time employees of Roche, Nutley, NJ, USA. Neil Buss is a full-time employee of Roche, Basel, Switzerland.

Author information

Authors and Affiliations

  1. Roche, 340 Kingsland Street, Nutley, New Jersey, 07110, USA

    Indravadan H. Patel, Xiaoping Zhang, Keith Nieforth & Miklos Salgo

  2. Roche, Basel, Switzerland

    Neil Buss

Authors
  1. Indravadan H. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith Nieforth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miklos Salgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neil Buss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Indravadan H. Patel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, I.H., Zhang, X., Nieforth, K. et al. Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of Enfuvirtide. Clin Pharmacokinet 44, 175–186 (2005). https://doi.org/10.2165/00003088-200544020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200544020-00003

Keywords

Search

Navigation